VCYT240517C30000
- 0.05
- 0.000.00%
Veracyte Newsroom
Express News | Veracyte Announces Multiple Afirma Grid Presentations at Endo 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
Veracyte (VCYT) Up 6% Since Last Earnings: Will It Continue?
Veracyte to Participate in Upcoming Investor Conferences
Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, today announced it will participate in the following investor conferences.
An Intrinsic Calculation For Veracyte, Inc. (NASDAQ:VCYT) Suggests It's 35% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Veracyte fair value estimate is US$34.38 Veracyte is estimated to be 35% undervalued based on current share price of US$22.50 Our fair valu
Veracyte's Strong Q1 Performance and Upbeat Outlook Justify Buy Rating
Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT) and Argenx Se (ARGX)
Veracyte | 10-Q: Quarterly report
Veracyte, Inc. (NASDAQ:VCYT) Q1 2024 Earnings Call Transcript
A Glimpse Into The Expert Outlook On Veracyte Through 4 Analysts
4 analysts have expressed a variety of opinions on Veracyte (NASDAQ:VCYT) over the past quarter, offering a diverse set of opinions from bullish to bearish.The table below summarizes their recent rati
Veracyte (VCYT) Reports Narrower Q1 Loss, Raises '24 Sales View
Veracyte Price Target Cut to $27.00/Share From $33.00 by Needham
Veracyte Price Target Cut to $27.00/Share From $33.00 by Needham
Veracyte Is Maintained at Buy by Needham
Veracyte Is Maintained at Buy by Needham
Express News | Needham Maintains Buy on Veracyte, Lowers Price Target to $27
Veracyte Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 20.54% Needham $33 → $27 Maintains Buy 04/15/2024 25% Goldman Sachs $32 → $28 Maintains Buy 02/
Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT), Veracyte (VCYT) and Nevro Corp (NVRO)
Express News | Veracyte Inc : Needham Cuts Target Price to $27 From $33
Maintaining Buy on Veracyte: Strong Q1 Performance and Progress Toward Profitability
Veracyte Inc (VCYT) (Q1 2024) Earnings Call Transcript Highlights: Strong Start With Revenue ...
Veracyte Q1 2024 GAAP EPS $(0.02) Beats $(0.17) Estimate, Sales $96.844M Beat $93.370M Estimate
Veracyte (NASDAQ:VCYT) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.17) by 88.24 percent. This is a 81.82 percent increase over losses of $(0.11) per
Veracyte Inc (VCYT) Q1 2024 Earnings: Surpasses Revenue Forecasts With Strong Test Performance